SlidesetHIVResistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhDView Slideset
SlidesetHIVSwitching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhDView Slideset
SlidesetHIVLonger duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele ArmeniaView Slideset
SlidesetHIVIntegrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSCView Slideset
SlidesetHIVLong-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCPView Slideset
SlidesetHIVPharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmDView Slideset
